Search

Your search keyword '"Orias, Marcelo"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Orias, Marcelo" Remove constraint Author: "Orias, Marcelo"
49 results on '"Orias, Marcelo"'

Search Results

1. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

2. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension

5. Novel Molecules

6. Personalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial

7. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

8. Sao Paulo call to action for the prevention and control of high blood pressure: 2020/Chamado a acao de Sao Paulo para prevencao e controle da hipertensao arterial, 2020/Llamado a la accion de San Pablo para la prevencion y el control de la hipertension arterial, 2020

9. It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives

10. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients

12. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action

14. Caracterización de presión arterial en pacientes con enfermedad de Fabry con MAPA

16. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action

21. Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk.

22. Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative

25. Cloning and localization of a double-pore K channel, KCNK1: exclusive expression in distal nephron segments

27. Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk : An International Expert Consultation

28. Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation

30. Estimated GFR or Albuminuria: Which One Is Really Associated With Resistant Hypertension?

31. KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels

32. Resources for Blood Pressure Screening Programs in Low Resource Settings: A Guide From the World Hypertension League

33. PREVALENCE OF FACTORS RELATED TO VASCULAR CALCIFICATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS.

34. 2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation.

35. High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology.

36. Global Implications of Blood Pressure Thresholds and Targets: Guideline Conversations From the World Hypertension League.

39. Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients

46. Caracterización de presión arterial en pacientes con enfermedad de Fabry con MAPA

47. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

48. [Implementation of the HEARTS Initiative in Argentina: initial resultsImplementação da Iniciativa HEARTS na Argentina: primeiros resultados].

49. Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk.

Catalog

Books, media, physical & digital resources